Eleni Gavriilaki, MD, PhD, G Papanicolaou Hospital, Thessaloniki, Greece, talks on the outcomes of patients with FLT3-mutated acute myeloid leukemia (AML) who relapse after allogeneic hematopoietic stem cell transplantation (alloHSCT), sharing her excitement for the upcoming approval of FLT3 inhibitors in this setting. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.